Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with poor outcomes, particularly in recurrent/metastatic settings.
• Current treatments like surgery, radiation, chemotherapy, and immune checkpoint inhibitors show limitations due to tumor heterogeneity, immune evasion, and resistance.
• Chimeric Antigen Receptor (CAR) T-cell therapy has transformed hematologic cancer treatment but faces hurdles in solid tumors like HNSCC.

Purpose of the Study:

• To review the current status of CAR T-cell therapy for HNSCC.
• To identify potential CAR T-cell targets and discuss challenges in solid tumor application.
• To explore innovative strategies and future therapeutic potential of CAR T-cells in HNSCC.

Main Methods:

• Literature review of CAR T-cell therapy mechanisms, targets, and strategies in HNSCC.
• Analysis of challenges including tumor microenvironment (TME) immunosuppression and antigen heterogeneity.
• Examination of emerging approaches like dual-targeting, armored CARs, and combination therapies.

Main Results:

• Several tumor-associated antigens (TAAs) like EGFR, HER2, B7-H3, CD44v6, CD70, CD98, and MUC1 are identified as potential CAR T-cell targets in HNSCC.
• Innovative strategies such as dual-targeting CARs, armored CARs, and CRISPR modifications are being developed to enhance efficacy.
• Combination therapies with immune checkpoint inhibitors and TGF-β-resistant CAR designs show promise for improved outcomes.

Conclusions:

• CAR T-cell therapy holds significant potential for treating HNSCC, despite existing challenges.
• Overcoming TME-induced immunosuppression and antigen heterogeneity is crucial for successful translation.
• Further research into novel targets, advanced CAR designs, and combination strategies is essential to realize the full therapeutic potential in HNSCC.